When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Celgene (CELG) has seen its stock price improve dramatically since it was announced it would be acquired by Bristol-Myers Squibb (BMY). The deal was approved by stockholders of both companies and looks likely to go through this year, unless there are regulatory objections. Currently, Celgene's stock price is near the cash value of the deal $50 per share, plus the price of one BMY share. But there is another potential asset in the deal: CVRs (contingent value rights). Right now these appear to be valued at zero. Here I will discuss